Shares of OncoSec Medical Incorporated (NASDAQ:ONCS) have earned an average recommendation of “Buy” from the six analysts that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $5.33.
ONCS has been the topic of a number of recent research reports. Maxim Group reaffirmed a “buy” rating and set a $5.00 price objective on shares of OncoSec Medical in a report on Friday, May 12th. HC Wainwright set a $6.00 price objective on OncoSec Medical and gave the company a “buy” rating in a report on Monday, May 22nd. ValuEngine downgraded OncoSec Medical from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. Noble Financial reissued a “buy” rating on shares of OncoSec Medical in a report on Friday, May 12th. Finally, Dawson James reissued a “buy” rating and issued a $5.00 target price on shares of OncoSec Medical in a report on Thursday, July 6th.
Shares of OncoSec Medical (NASDAQ ONCS) opened at 0.9901 on Tuesday. The company’s 50 day moving average price is $1.10 and its 200-day moving average price is $1.20. OncoSec Medical has a 12 month low of $0.88 and a 12 month high of $2.08. The firm’s market capitalization is $20.96 million.
OncoSec Medical (NASDAQ:ONCS) last released its quarterly earnings data on Thursday, June 1st. The biotechnology company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.06. On average, equities analysts predict that OncoSec Medical will post ($1.02) earnings per share for the current fiscal year.
About OncoSec Medical
OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation.
Receive News & Ratings for OncoSec Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.